Objective: Oxidative stress has been reported to play a role in the psychopathology of schizophrenia, though only a few studies have investigated the relationship between early-onset schizophrenia and oxidative stress. The aim of the present study is to evaluate the level of oxidative stress and the presence of DNA damage in first-episode psychosis (FEP) in adolescents. Methods: This study was conducted in the Department of Child Psychiatry of the Dicle University Hospital. It included 20 adolescent patients (age 11-17 years) with psychosis (acute psychosis, schizophreniform disorder, or schizophrenia) according to DSM-IV criteria who had received no previous psychiatric therapy (patient group) and 20 age/gender-matched healthy adolescents (control group). Structured psychiatric interviews [Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime Version (K-SADS-PL) and Positive and Negative Symptom Scale (PANSS)] were conducted on the patients, and the Clinical Global Impressions (CGI) scale was used to evaluate the severity of disease. Glutathione peroxidase (GPx), superoxide dismutase (SOD), coenzyme Q (CoQ), and 8-hydroxy-2-deoxyguanosine (8-OHdG) levels were determined using the ELISA method and commercial ELISA kits. Results: The mean age was 14.5 ± 1.6 years in the FEP group (male-to-female ratio: 8/12) and 14.4 ± 1.5 years in the control group (male-to-female ratio: 8/12). There were no differences between the patient and control groups in terms of SOD, GPx, or 8-OHdG values (p > 0.05). Conclusions: This study on DNA damage and oxidative stress in FEP in adolescents had a small sample size, and our data suggest that oxidative stress is associated with a chronic disease course rather than being an early sign of early-onset schizophrenia.

Keywords:
Oxidative stress, DNA damage, Early-onset schizophrenia, First-episode psychosis
1.
Joa I, Johannessen JO, Langeveld J, Friis S, Melle I, Opjordsmoen S, et al: Baseline profiles of adolescent vs. adult-onset first-episode psychosis in an early detection program. Acta Psychiatr Scand 2009;119:494-500.
2.
Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, et al: Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008;34:60-71.
3.
Häfner H, Nowotny B: Epidemiology of early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 1995;245:80-92.
4.
Reichert A, Kreiker S, Mehler-Wex C, Warnke A: The psychopathological and psychosocial outcome of early-onset schizophrenia: preliminary data of a 13-year follow-up. Child Adolesc Psychiatry Ment Health 2008;2:6.
5.
Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S: Brain derived neurotropic factor in first-episode psychosis. Schizophr Res 2007;91:1-5.
6.
Wood SJ, Yücel M, Pantelis C, Berk M: Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann Acad Med Singapore 2009;38:396-401.
7.
McQuillen PS, Ferriero DM: Selective vulnerability in the developing central nervous system. Pediatr Neurol 2004;30:227-235.
8.
Berg D, Youdim MB, Riederer P: Redox imbalance. Cell Tissue Res 2004;318:201-213.
9.
Wood SJ, Berger GE, Wellard RM, Proffitt T-M, McConchie M, Berk M, et al: Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol Dis 2009;33:354-357.
10.
Li J, O W, Li W, Jiang Z-G, Ghanbari HA: Oxidative stress and neurodegenerative disorders. Int J Mol Sci 2013;14:24438-24475.
11.
Hovatta I, Juhila J, Donner J: Oxidative stress in anxiety and comorbid disorders. Neurosci Res 2010;68:261-275.
12.
Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84.
13.
Massaad CA, Klann E: Reactive oxygen species in the regulation of synaptic plasticity and memory. Antioxid Redox Signal 2011;14:2013-2054.
14.
Beal MF: Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic Res 2002;36:455-460.
15.
Berk M: Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol 2009;12:441-445.
16.
Li XF, Zheng YL, Xiu MH, Chen DC, Kosten TR, Zhang XY: Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1064-1067.
17.
Yao JK, Reddy R: Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid Redox Signal 2011;15:1999-2002.
18.
Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY: Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 2003;117:85-88.
19.
Chittiprol S, Venkatasubramanian G, Neelakantachar N, Babu SVS, Reddy NA, Shetty KT, et al: Oxidative stress and neopterin abnormalities in schizophrenia: a longitudinal study. J Psychiatr Res 2010;44:310-313.
20.
Padurariu M, Ciobica A, Dobrin I, Stefanescu C: Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 2010;479:317-320.
21.
Martinez-Cengotitabengoa M, Antonio Mico J, Arango C, Castro-Fornieles J, Graell M, Paya B, et al: Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis: a 2-year follow-up study. Schizophr Res 2014;156:23-29.
22.
Fraguas D, Gonzalez-Pinto A, Antonio Mico J, Reig S, Parellada M, Martinez-Cengotitabengoa M, et al: Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study. Schizophr Res 2012;137:58-65.
23.
Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980-988.
24.
Gökler B, Ünal F, Pehlivantürk B, Kültür EÇ, Akdemir D, Taner Y: Reliability and Validity of Schedule for Affective Disorders and Schizophrenia for School Age Children-Present and Lifetime Version-Turkish Version (K-SADS-PL-T). Turk J Child Adolesc Ment Health 2004;11:109-116.
25.
Kay SR, Fizsbein A, Obler LA, Lewis A: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:161-176.
26.
Kostakoğlu AE, Batur S, Tiryaki A, Gogus A: Pozitif ve negatif sendrom ölçeğinin (PANSS) Türkçe uyarlamasının geçerlik ve güvenilirliği. Türk Psikol Derg 1999;14:23-32.
27.
Guy W: Clinical Global Impressions; in ECDEU Assessment Manual for Psychopharmacology. Rockville, US Department of Health, Education, and Welfare, 1976, pp 218-222.
28.
Wei Y-C, Zhou F-L, He D-L, Bai J-R, Ding H, Wang X-Y, et al: Oxidative stress in depressive patients with gastric adenocarcinoma. Int J Neuropsychopharmacol 2009;12:1089-1096.
29.
Martínez-Cengotitabengoa M, Mac-Dowell KS, Leza JC, Micó JA, Fernandez M, Echevarría E, et al: Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res 2012;137:66-72.
30.
Micó JA, Rojas-Corrales MO, Gibert-Rahola J, Parellada M, Moreno D, Fraguas D, et al: Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMC Psychiatry 2011;11:26.
31.
Bitanihirwe BK, Woo T-UW: Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011;35:878-893.
32.
Raffa M, Atig F, Mhalla A, Kerkeni A, Mechri A: Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 2011;11:124.
33.
Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A: Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1178-1183.
34.
Wu Z, Zhang XY, Wang H, Tang W, Xia Y, Zhang F, et al: Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms. Prog Neuropsychopharmacol Biol Psychiatry 2012:10;36:34-38.
35.
Jorgensen A, Broedbaek K, Fink-Jensen A, Knorr U, Soendergaard MG, Henriksen T, et al: Increased systemic oxidatively generated DNA and RNA damage in schizophrenia. Psychiatry Res 2013;209:417-423.
36.
Wood SJ, Yücel M, Pantelis C, Berk M: Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann Acad Med Singapore 2009;38:396-401.
37.
Nishioka N, Arnold SE: Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2004;12:167-175.
38.
Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, et al: Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One 2008;3:e1944.
39.
McClellan J, Werry J, Bernet W, Arnold V, Beitchman J, Benson RS, et al: Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2001;40:4S-23S.
40.
Helenius D, Munk-Jørgensen P, Steinhausen H-C: Family load estimates of schizophrenia and associated risk factors in a nation-wide population study of former child and adolescent patients up to forty years of age. Schizophr Res 2012;139:183-188.
41.
Lopez-Castroman J, Gómez DD, Belloso JJC, Fernandez-Navarro P, Perez-Rodriguez MM, Villamor IB, et al: Differences in maternal and paternal age between Schizophrenia and other psychiatric disorders. Schizophr Res 2010;116:184-190.
42.
Goriely A, Wilkie AO: Paternal age effect mutations and selfish spermatogonial selection: causes and consequences for human disease. Am J Hum Genet 2012;90:175-200.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.